Introduction {#sec1-1}
============

Gastric cancer is the fifth most common cancer in the world and the third major cause of cancer-related deaths (Stewart and Wild, 2014). Incidence of gastric cancer in different geographical regions has a wide diversity. Developing countries include more than 70% of incident cases and deaths(Crew and Neugut, 2006).

The most frequent type of cancer during 1980s was the stomach cancer (Wu et al., 2002). Stomach cancer, with approximately 870,000 new patients per year, is the second most common cancer worldwide (Sentani et al., 2008; Ferlay et al., 2010).

At the moment, it has been shown that the progression of gastric cancer is related to underlying gastric diseases (like gastritis, gastrectomy, etc.) (Rugge et al., 2014), Helicobacter pylori (H. pylori) infection (Gatti et al., 2004), and genetic susceptibility factors (Gatti et al., 2004; Xie et al., 2014).

There have been several reports on interleukins in recent years (Cheng et al., 2013; Kim et al., 2014; Kutikhin et al., 2014) that explain gene polymorphisms at many loci can increase the risk of developing gastric cancer. Human interleukin-6 (IL-6) gene, the pro-inflammatory cytokine, is located on chromosome 7p21 and is composed of five exons and four introns. This multifunctional cytokine interferes in the maturation and differentiation of immune system (Kakumu et al., 1993; Galun et al., 2000). IL-6 gene promoter region has three single nucleotide polymorphisms (SNP) at positions -597 G/A, -572 G/A, and -174 G/C. Previous studies indicated a cooperative impact of these SNPs on IL-6 transcription regulation (Fishman et al., 1998; Terry et al., 2000).

Based on prior findings, the polymorphism of IL-6 gene position -174 G/C (rs1800795) is related to some diseases like diabetes (Fernandez-Real et al., 2000; Hamid et al., 2005), Alzheimer (Capurso et al., 2004), Hepatitis B (Attar et al., 2016), and multiple sclerosis (MS) (Shahbazi et al., 2010).

IL-6 is a phosphorylated glycoprotein and composed of 185 amino acids involved in various physiologic and pathophysiologic processes such as inflammation, bone metabolism, and synthesis of C-reactive protein (CRP). It plays a significant role in the development and progression of many forms of cancer (Mantovani et al., 2002; Salgado et al., 2003; Bozcuk et al., 2004), especially gastric cancer (Asschert et al., 1999; Diehl and Rincón, 2002; Lu et al., 2015).

Malekzadeh et al., (2009) in a review article expressed that high-risk areas for gastric cancer in Iran are northern and northwestern regions. The aim of this study was to evaluate whether IL-6 -174 G/C promoter polymorphisms are related to gastric cancer resistance in an Iranian population in the north of Iran.

Material and Methods {#sec1-2}
====================

Samples {#sec2-1}
-------

Fresh peripheral blood samples of gastric cancer patients (including esophageal, colon, stomach, and rectum) were collected from 100 5FU patients who referred to 5th Azar hospital, Hakim Jorjani hospital, and Moosavi hospital of Golestan province and were treated during 2011. They were also taken from 361 healthy controls without a history of cancers who referred to Gorgan blood donation centers in Golestan province of Iran (5 ml peripheral blood collected in falcon tubes contained EDTA).

DNA extraction {#sec2-2}
--------------

DNA was extracted using the phenol-chloroform method by modified standard protocol (Shahbazi et al., 2002). The concentration was determined by spectrophotometer at 260 nm (Techne, UK) and DNA samples were maintained in -20°C.

Genotyping {#sec2-3}
----------

The SSP-PCR (sequence-specific primer-polymerase chain reaction) method (Mansoori et al., 2015) was used for genotyping of cancer cases (n=100) and the control group (n=361) by primers: Forward1: 5´-CCC CTA GTT GTG TCT TGC C-3´for allele C, Forward2: 5´-CCC CTA GTT GTG TCT TGC G-3´ for allele G and generic primer: 5´-GCC TCA GAG ACA TCA CCA GTC C-3´. Primers used for human growth hormone (HGH) as an internal control were Forward: 5-GCCTTCCCAACCATTCCCTTA-3 and Revers: 5-TCACGGATTTCTGTTGTGTTTC-3. Each PCR reaction included 100--150 ng of DNA and 9.5 ml master mix containing 20 mM dNTP, 1X Ready load PCR buffer, 12% Sucrose (Merck, Germany), Two unit Taq DNA polymerase (GenetBio, Korea), 6 mM HGH primer, and 30 mM of each specific IL-6 primer.

The PCR reaction was carried out in a Thermal Cycler (Techne, UK), with the following program: 1min at 95°C followed by 10 cycles of 15 s at 95°C, 50 s at 58°C, 40 s at 72°C, then, 20 cycles of 20 s at 95°C, 50 s at 54°C and 50s at 72°C, with 5min at 72°C as the final extension.

PCR product was submitted to electrophoresis in 1.5% agarose gel (Merck, Germany) and stained with Safe Stain (CinaGene, Iran). Using a gel documentation system (UVITEC, UK), DNA bands were visualized under the UV radiation.

Statistical analysis {#sec2-4}
--------------------

Web program (<http://ihg.gsf.de/cgi-bin/hw/hwa2.pl>) was applied for testing the genotype results for deviation from Hardy-Weinberg equilibrium. Statistical analysis was done by the Statistical Program for Social Sciences (SPSS version 17.0) and the means of parametric variables were calculated. For parametric and non-parametric values, data were presented as Mean±SD and percentage, respectively. After calculating Alleles and genotype frequencies, results compared with non-parametric tests followed by Fisher's exact analysis using STATA v-8 (CA, US). P-values were determined and those less than 0.05 were considered to be significant.

Results {#sec1-3}
=======

In the present study, frequency of the IL-6 -174 G/C genotypes was evaluated in 100 gastric cancer patients and 361 controls under Co-dominant, Dominant and Recessive genetic models. As showed in [Table 1](#T1){ref-type="table"}, there was an association between polymorphism of IL-6 -174 G/C and susceptibility to gastric cancer in various genetic models. G allele was more frequent in patients (78%) than in controls (70.5 %) under co-dominant genetic model (OR=1.48, 95% CI=1.01-2.20, P=0.04).

###### 

Frequency of the IL-6 -174 G/C Genotypes among Patients (N=100) and Controls (N=361) Under Co-Dominant, Dominant, and Recessive Models

                         Controls       Case         OR (95% CI)[\*](#t1f1){ref-type="table-fn"}   P-value
  ---------------------- -------------- ------------ --------------------------------------------- ---------
   C/C                   13 (3.6 %)     7 (7 %)      1 (-)[\*\*](#t1f2){ref-type="table-fn"}       \-
   C/G                   187 (51.8%)    30 (30 %)    0.3 (0.1-0.96)                                0.02
   G/G                   161 (44.6%)    63 (63 %)    0.72 (0.25-2.26)                              0.6
   C                     213(29.5 %)    44 (22 %)    1 (-)                                         \-
   G                     509 (70.5 %)   156 (78 %)   1.48 (1.01-2.20)                              0.04
  Model of Inheritance                                                                             
  Dominant                                                                                         
   C/C                   13 (3.6 %)     7 (7 %)      1 (-)                                         \-
   C/G + G/G             348 (96.4%)    93 (93%)     0.49 (0.18-1.51)                              0.16
  Recessive                                                                                        
   C/G + C/C             200 (55.4%)    37 (37%)     1 (-)                                         \-
   G/G                   161 (44.6%)    63 (63 %)    2.11 (1.31-3.44)                              0.0015
  Co-dominant                                                                                      
   C/C + G/G             174 (48.2%)    70 (70%)     2.5 (1.5-4.18)                                0.0001
   C/G                   187 (51.8%)    30 (30 %)    1 (-)                                         \-

, OR, odds ratio; CI, confidence interval;

, The frequency of C allele was higher in the control group, so it was selected as a reference group.

Patients were classified into five age groups, namely, less than 39 years, 40-49 years, 50-59 years, 60-69 years and, more than 70 years. Frequency of four different types of gastric cancer was analyzed within these age groups which is evaluated and presented in [Table 2](#T2){ref-type="table"}.

###### 

Frequency of Four Different Types of Gastric Cancer within Age

              Age        Total                                               
  ----------- ---------- ------------ ------------ ------------ ------------ --------------
  Esophagus   1 (2.6%)   2 (5.1%)     8 (20.5%)    12 (30.8%)   16 (41.0%)   39 (100.0%)
  Colon       3 (6.4%)   15 (31.9%)   12 (25.5%)   9 (19.1%)    8 (17.0%)    47 (100.0%)
  Stomach     0 (.0%)    3 (27.3%)    2 (18.2%)    2 (18.2%)    4 (36.4%)    11 (100.0%)
  rectum      0 (.0%)    2 (66.7%)    0 (.0%)      0 (.0%)      1 (33.3%)    3 (100.0%)
  Total       4 (4.0%)   22 (22.0%)   22 (22.0%)   23 (23.0%)   29 (29.0%)   100 (100.0%)

Evaluation of disease prevalence by gender revealed most patients were male (69.0%). Complementary data are provided in [Table 3](#T3){ref-type="table"}.

###### 

Frequency of Four Different Types of Gastric Cancer Cases within Sex

              Sex          Total        
  ----------- ------------ ------------ --------------
  Esophagus   29 (74.4%)   10 (25.6%)   39 (100.0%)
  Colon       31 (66.0%)   16 (34.0%)   47 (100.0%)
  Stomach     8 (72.7%)    3 (27.3%)    11 (100.0%)
  rectum      1 (33.3%)    2 (66.7%)    3 (100.0%)
  Total       69 (69.0%)   31 (31.0%)   100 (100.0%)

Discussion {#sec1-4}
==========

So far, we have examined the association of several genes with cancer (Abdolmohammadi et al., 2016; Attar et al., 2016; Azar et al., 2016; Mansoori et al., 2016; Shamsabadi et al., 2016). In this evaluation, frequency of the IL-6 -174 G/C genotypes was assayed under Co-dominant, Dominant, and Recessive genetic models in gastric cancer patients compared with healthy population. A highly statistically significant difference in the frequency of the G allele was observed between patients and controls (OR=1.48, 95% CI=1.01-2.20, P=0.04). G allele at the position IL-6 -174 had higher distribution among patients in comparison to controls. Recessive and Co-dominant analysis models of this polymorphism also revealed a significant difference between cases and controls ([Table 1](#T1){ref-type="table"}).

AM Sampaio et al., (2015) in Portugal stated that IL-6 -174 C/G genotype showed a higher prevalence among gastric cancer cases. Landi et al., (2003) determined the IL-6 -174C genotype is associated with increased risk of colorectal cancer. Ruzzo et al., (2014) demonstrated that IL-6 gene polymorphism can increase the risk of developing gastric cancer. On the contrary, the result of a meta-analysis by Yin et al., (2012) showed that polymorphism of IL-6 -174 C/G is not associated with the risk of gastric cancer.

Some previous studies examined the IL-6 serum level and illustrated the relationship of IL-6 gene overexpression and the increased risk of cancers (Waldner et al., 2012; Woo and Humphries, 2013). Accordingly, Ruzzo et al., (2014) hypothesized that anti-IL-6 compounds can be used as novel therapeutics in treatment of cancer patients (Ruzzo et al., 2014). Belluco et al., (2003) showed that -174 C/G polymorphism of interleukin-6 gene promoter affects interleukin-6 serum level in patients with colorectal cancer.

Although we did not assay the IL-6 serum level in our study, it is estimated that there is an association between genotype and expression level of IL-6 gene.

Evaluation of frequency of four different types of gastric cancer in patients demonstrated that colon cancer was the most common type (47%) of gastric cancer and then esophageal (39%), stomach (11%) and rectum (3%) cancer were more abundant, respectively ([Table 2](#T2){ref-type="table"}).

Previous studies have shown that the age at disease onset is over 55 and men are more likely to be affected than women (Pinto et al., 1994; Axon, 2006). In a review article, Malekzadeh R. et al. showed that age-standardized incidence rate (ASR) of men and women was 27.8 and 8.3, respectively, in Golestan province of Iran (Malekzadeh et al., 2009). Investigating frequency of four different types of gastric cancer within age in our patients shows that there is a direct relationship between aging and increased incidence of esophagus cancer whereas there is not such a relationship in other types of gastric cancer ([Table 2](#T2){ref-type="table"}).

Examining frequency of gastric cancer within gender also shows that the prevalence of gastric cancer in men (69.0%) is more than women (31%) ([Table 3](#T3){ref-type="table"}). These results suggest that polymorphism of IL-6 -174 C/G may influence the susceptibility of women gender to this cancer. On the other hand, high prevalence of the disease in men may be due to environmental factors like smoking or high intake of salt and alcohol and etc.

In conclusion, these findings suggest that IL-6 -174 G/C polymorphism may influence the susceptibility to gastric cancer.
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